TSE:MFC

Manulife Financial (MFC.TO)

60.67
+0.26 (0.43%)
as of Jul 22, 2026, 8:00:00 pm Market Open.
1632 watching
0
Investor Insights
star iconJul 22, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has garnered a mostly positive outlook among various experts, highlighting its competitive positioning within the Canadian financial sector, particularly in comparison to major banks like TD and SLF. Analysts note MFC's ongoing strength in wealth management and healthy growth prospects in Asia, although there are concerns regarding its current valuation, as it trades over 2x book value and exhibits only moderate earnings growth. Despite being classified as slightly overbought, its charts remain healthy, with many recommending caution yet seeing potential for growth in the long run. The company's strong dividend yield and management strategies, particularly in alternative investments, also contribute to a favorable long-term investment story, although short-term volatility may present opportunities for those willing to enter at lower price points.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
SLF,SLF
BUY
Financials do well now into mid-April. MFC could be a good long-term hold. MFC is performing well now and could return to $28. If it break above $28, MFC could do very well.
WATCH
Why doesn't it trade higher? Over the last year, an investor would rather hold a bank that had never cut its dividend, instead of MFC, which has cut in the past. So MFC won't see the same multiple in uncertain economic times such as now. Going forward, lots of promise. In Asia, a big growth area. Won't have same bank issues with net interest margin or bad debt. Should do well on the other side of a recession. Valuation fairly good, dividend not likely to be cut anytime soon. He's looking at it.
PAST TOP PICK
(A Top Pick Jan 12/22, Up 4%) Very good cashflow dividend of 5.2% today. Trades below book value, .95 price to book. Outpacing TSX since last May, a good technical sign. Remains a top 3 pan-Asian life insurer. Growth of middle class long term a definite positive. Looser China Covid rules will spur sales. Keep holding.
TOP PICK
Trading at less than its book value, it is very inexpensive. Investors are worried about how insurance companies will do next year under the new accounting regime standards, which will greatly affect the way they book profits and new business. But MFC won't change the way they manage their reserve requirements. This an accounting change, not necessarily a real world change. There is a lot of legacy business left over and this has helped to cause MFC to lag. If this is taken out of the long term care business, as well as low ROE business in the U.S., the stock should start to go up. Buy 7 Hold 8 Sell 1 (Analysts’ price target is $26.21)
BUY
Below NAV. With bond yields recovering, lifecos are finally back in the sweet spot of making money on investments. Spreads on unearned premiums are going to increase, so analysts should redo their models. China is opaque, mysterious, and that makes him nervous. Compelling buy at these prices.
BUY
Dividend play with its 5.5% yield. Most exposure to Asia among peers, a drag the last year. Asia and China are opening up, starting to be a tailwind again. Likes it at current levels.
DON'T BUY
Seemingly a great business, but look at how good it is at reinvesting into the business over the long term. Unable to show they can deliver sustainable higher ROE. Nice dividend, safe. He prefers more growth, such as TSU or IFC.
HOLD
Really likes it for the dividend of 5.56%. Safe dividend. Below book value at 0.9x. Starting to break out a bit. Be patient. As the macro improves in 2023-24, shares in the insurance market should improve also.
BUY
Lifecos are entering reporting season. Investors will look to see how Asian sales impacted in recent environment. Extremely well-financed. Dividend certainly secure, likely to grow. He'd recommend today as a good, long-term hold.
BUY
MFC vs. SLF vs. TD All financials got beaten up. Issue with banks is potential loan losses, and if it's a deep recession, loan losses can get bigger. A lot of financials can be a black box, and you don't see the damage until it's too late. Impressed by what MFC has done over time, nice dividend yield. All financials are starting to look interesting. Banks look attractive valuation-wise, but he'd wait.
BUY
Likes company with strong dividend (expecting rise in the future). Past troubles of the business has led to conservative balance sheet. High interest rates good for insurance companies. Competition from bond yields impacting value of shares.
BUY
His favourite lifeco is GWO. MFC is well run, but has a different regional focus, China, higher-grown and emerging. Valuation trades near book value and pays around a 6% dividend. There's tremendous value in lifecos. MFC ticks all the boxes.
DON'T BUY
It always trades in the same range. What kind of value is being created? Can't seem to deploy excess capital efficiently. See his Top Picks. Don't be seduced by the dividend.
DON'T BUY
It's been stuck in the doldrums for 5-6 years. It doesn't grow like the banks. Currency meltdowns hurt MFC's big Asian division.
DON'T BUY
Hard to own insurance, as there are so many moving parts. Insurance arm in Asia starting to slow down. Cheap valuation. Unclear what motivation is to move higher. Not a fan, or of any insurance. Benefit of rising rates offset by poor equity markets.
Showing 151 to 165 of 2,283 entries